Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia

Schizophrenia Research

Volumn 118, Issue 1-3, 2010, Pages 176-182

  Kinon, Bruce J ^a   Chen, Lei ^a   Ascher Svanum, Haya ^a   Stauffer, Virginia L ^b   Kollack Walker, Sara ^b   Zhou, Wei ^b   Kapur, Shitij ^c   Kane, John M ^d   Naber, Dieter ^e  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly USA   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

^e NONE

Author keywords

Atypical antipsychotic; Early response; Prediction; Risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; CHRONIC PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SUBSTITUTION; EFFECT SIZE; EMOTIONALITY; FUNCTIONAL ASSESSMENT; HUMAN; INTEGRATION; MAJOR CLINICAL STUDY; MENTAL FUNCTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PRODUCTIVITY; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIA OBJECTIVE FUNCTIONING INSTRUMENT; SELF CONTROL; SUBJECTIVE WELL BEING UNDER NEUROLEPTICS SCALE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951978411     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.12.013     Document Type: Article

References (27)

1. Arango C., Buchanan R.W., Kirkpatrick B., Carpenter W.T. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur. Psychiatry 2004, 19(1):21-26.
2. Ascher-Svanum H., Nyhuis A.W., Faries D.E., Kinon B.J., Baker R.W., Shekhar A. Clinical, functional and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr. Bull. 2008, 34(6):1163-1171.
3. Breier A., Meehan K., Birkett M., David S., Ferchland I., Sutton V., Taylor C.C., Palmer R., Dossenbach M., Kiesler G., Brook S., Wright P. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry 2002, 59(5):441-448.
4. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33(4):1013-1022.
5. Carpenter W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 1988, 145(5):578-583.
6. Carpenter W.T., Kirkpatrick B. The heterogeneity of the long-term course of schizophrenia. Schizophr. Bull. 1988, 14(4):645-652.
7. Carpenter W.T., Koenig J.I. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008, 33(9):2061-2079.
8. Chen L., Ascher-Svanum H., Stauffer V., Kinon B.J., Kollack-Walker S., Ruberg S. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr. Res. 2009, 113(1):34-40.
9. Correll C.U., Malhotra A.K., Kaushik S., McMeniman M., Kane J.M. Early prediction of antipsychotic response in schizophrenia. Am. J. Psychiatry 2003, 160(11):2063-2065.
10. Kleinman L., Lieberman J., Dube S., Mohs R., Zhao Y., Kinon B., Carpenter W., Harvey P.D., Green M.F., Keefe R.S., Frank L., Bowman L., Revicki D.A. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophr. Res. 2009, 107(2-3):275-285.
11. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10(3):388-398.
12. Jones B., Taylor C.C., Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J. Clin. Psychiatry 2001, 62(suppl 2):22-24.
13. Karow A., Pajonk F.-G., Reimer J., Hirdes F., Osterwald C., Naber D., Moritz S. The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(3):152-159.
14. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
15. Kinon B.J., Chen L., Ascher-Avanum H., Stauffer V.L., Kollack-Walker S., Sniadecki J.L., Kane J.M. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr. Res. 2008, 102(1-3):230-240.
16. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., Kapur S., Kane J.M. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590.
17. Lehman A.F. Developing an outcomes-oriented approach for the treatment of schizophrenia. J. Clin. Psychiatry 1999, 60(suppl 19):30-35.
18. Leucht S., Busch R., Kissling W., Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J. Clin. Psychiatry 2007, 68(3):352-360.
19. Leucht S., Shamsi S.A., Busch R., Kissling W., Kane J.M. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr. Res. 2008, 101(1-3):312-319.
20. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:381-389.
21. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life and other clinical variables. Int. Clin. Psychopharmacol. 1995, 10(Supp.3):133-138.
22. Naber D., Moritz S., Lambert M., Rajonk F., Holzbach R., Mass R., Andresen B., Frank P., Rudiger H., Reinhard M., Burghard A. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 2001, 50(1-2):79-88.
23. Nicholson I.R., Chapman J.E., Neufeld R.W.J. Variability in BPRS definitions of positive and negative symptoms. Schizophr. Res. 1995, 17(2):177-185.
24. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10:799-812.
25. Wehmeier P.M., Kluge M., Schacht A., Helsberg K., Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr. Res. 2007, 91(1-3):178-186.
26. Wehmeier P.M., Kluge M., Schneider E., Schacht A., Wagner T., Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(3):703-712.
27. Yamauchi K., Aki H., Tomotake M., Iga J.-I., Numata S., Motoki I., Izaki Y., Tayoshi S., Kinouchi S., Sumitani S., Tayoshi S., Takikawa Y., Keneda Y., Taniguichi T., Ishimoto Y., Ueno S.-I., Ohmori T. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin. Neurosci. 2008, 62(4):404-411.